The global Immunotherapy Drugs Market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. North America is expected to account for largest share in the immunotherapy drugs market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.
Drivers
1 Increasing Adoption of Targeted Therapy Over Traditional Therapy
2 Emergence of Biosimilars
3 Increasing Demand for Mabs
4 High Prevalence Rate of Lifestyle Diseases
5 Fast Track and Orphan Drug Designations
Restraints
1 High Cost of Immunotherapy Treatment
2 High Attrition Rate in the Product Development Cycle
PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=137717755
Opportunities
1 Emerging Markets
2 Immunotherapy to Replace Chemotherapy in Cancer Treatment
Major Key Players:
The major players operating in the immunotherapy drugs market include F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.). Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Eli Lilly and Company (U.S.), Johnson & Johnson (U.S.), and AstraZeneca plc (U.K.).
